Metagenomi

Biotech · Private

CRISPR and gene editing systems derived from metagenomic discovery

metagenomi.co →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
12
1 granted · 11 pending
Sector median: 2

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2580SOUTHEAST TECHINVENTURES, INC.—$836K
2581RAPHAEL PHARMACEUTICALS LLC——
2582KaloCyte Inc—$800K
2583Metagenomi——
2584PRAETEGO, INC.—$783K
2585Indigo Biosciences Inc.—$782K
2586Bit Discovery, Inc.—$760K

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 1 granted of 12
  • Retrotransposon Compositions And Methods Of Useapplication
  • Serine Recombinases For Gene Editingapplication
  • Supplementation Of Liver Enzyme Expressiongranted
  • Compositions And Methods For Editing T Cellsapplication
  • Compositions And Methods For Editing T Cellsapplication
  • Class 2, Type V Crispr Systemsapplication
  • Supplementation Of Liver Enzyme Expressionapplication
  • Compositions And Methods For Editing T Cellsapplication
  • Base Editing Enzymesapplication
  • Base Editing Enzymesapplication
  • Systems And Methods For Transposing Cargo Nucleotide Sequencesapplication
  • Endonuclease Systemsapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.